← All trials
NCT05862272
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 14, 2023
- Primary completion
- Jul 31, 2029
- Completion date
- Sep 30, 2030
- First posted
- May 17, 2023
- Last posted
- Dec 20, 2023
- Enrollment
- 1000
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Myovant Sciences GmbHLead sponsor
- Myovant Sciences GmbHStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.